Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
RESEARCH TOOLSreports
BCLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $6.01
Previous CloseN/A
Volume34.73K
Average Volume (3M)325.08K
Market Cap
$5.94M
Enterprise Value$9.41M
Total Cash (Recent Filing)$1.64M
Total Debt (Recent Filing)$1.77M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 17, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding9,838,859
10 Day Avg. Volume83,207
30 Day Avg. Volume325,076
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$6.60Price Target Upside964.52% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressThe P3b study in ALS has been cleared by FDA, and the company plans to conduct the study under the Special Protocol Assessment.
Support For ApprovalThere is growing support for NurOwn's approval, driven by media coverage and independent advocacy, including a Citizens' Petition.
Survival DataBrainStorm announced new survival data from the Expanded Access Program for NurOwn cell therapy, showing that 90% of patients survived more than five years, compared to the average life expectancy for ALS patients of 2-5 years.
Bears Say
Capital NeedsBrainStorm reported a net loss and will need to raise additional capital to move forward with the P3b study of NurOwn.
Delisting ChallengesShares of BrainStorm Cell Therapeutics were downgraded to Hold due to capital needs and recent delisting.
Financial RiskThe company needs to raise capital and the delisting along with the sharp decline in the share price increases the risk of an incrementally dilutive financing.
Brainstorm Cell Therapeutics News
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.52 and its highest was $6.01 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $5.94M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 93 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.03.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 9,838,859 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
BCLI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.View all BCLI earnings summariesBCLI Stock 12 Month Forecast
Average Price Target
$6.60
▲(964.52% Upside)
Technical Analysis
Ownership Overview
8.06% Insiders
0.79% Mutual Funds
3.08% Other Institutional Investors
87.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---